S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
NYSE:ACB

Aurora Cannabis Competitors

$12.04
+0.08 (+0.67 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.85
Now: $12.04
$13.32
50-Day Range
$8.31
MA: $9.84
$11.96
52-Week Range
$3.71
Now: $12.04
$27.84
Volume45.62 million shs
Average Volume19.51 million shs
Market Capitalization$1.71 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.44

Competitors

Aurora Cannabis (NYSE:ACB) Vs. CRON, TLRY, USNA, HEXO, SNDL, and CDXC

Should you be buying ACB stock or one of its competitors? Companies in the industry of "medicinals & botanicals" are considered alternatives and competitors to Aurora Cannabis, including Cronos Group (CRON), Tilray (TLRY), USANA Health Sciences (USNA), HEXO (HEXO), Sundial Growers (SNDL), and ChromaDex (CDXC).

Cronos Group (NASDAQ:CRON) and Aurora Cannabis (NYSE:ACB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.

Valuation and Earnings

This table compares Cronos Group and Aurora Cannabis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$25.64 million151.66$1.17 billion$0.6716.31
Aurora Cannabis$207.89 million8.21$-2,468,190,000.00($2.86)-4.21

Cronos Group has higher earnings, but lower revenue than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cronos Group and Aurora Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cronos Group266.31%-1.61%-1.41%
Aurora Cannabis-1,238.94%-16.32%-13.12%

Institutional and Insider Ownership

11.8% of Cronos Group shares are owned by institutional investors. Comparatively, 11.9% of Aurora Cannabis shares are owned by institutional investors. 7.9% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Cronos Group has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 3.44, meaning that its stock price is 244% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Cronos Group and Aurora Cannabis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cronos Group24202.00
Aurora Cannabis412101.82

Cronos Group presently has a consensus price target of $8.1875, indicating a potential downside of 25.09%. Aurora Cannabis has a consensus price target of $12.6564, indicating a potential upside of 5.12%. Given Aurora Cannabis' higher probable upside, analysts clearly believe Aurora Cannabis is more favorable than Cronos Group.

Summary

Cronos Group beats Aurora Cannabis on 10 of the 14 factors compared between the two stocks.

Tilray (NASDAQ:TLRY) and Aurora Cannabis (NYSE:ACB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.

Valuation and Earnings

This table compares Tilray and Aurora Cannabis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tilray$166.98 million15.75$-321,170,000.00($1.69)-11.66
Aurora Cannabis$207.89 million8.21$-2,468,190,000.00($2.86)-4.21

Tilray has higher earnings, but lower revenue than Aurora Cannabis. Tilray is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tilray and Aurora Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tilray-259.60%-77.77%-21.45%
Aurora Cannabis-1,238.94%-16.32%-13.12%

Institutional and Insider Ownership

10.4% of Tilray shares are owned by institutional investors. Comparatively, 11.9% of Aurora Cannabis shares are owned by institutional investors. 16.8% of Tilray shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Tilray has a beta of 3.02, meaning that its stock price is 202% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 3.44, meaning that its stock price is 244% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Tilray and Aurora Cannabis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tilray210101.92
Aurora Cannabis412101.82

Tilray presently has a consensus price target of $12.2720, indicating a potential downside of 37.71%. Aurora Cannabis has a consensus price target of $12.6564, indicating a potential upside of 5.12%. Given Aurora Cannabis' higher probable upside, analysts clearly believe Aurora Cannabis is more favorable than Tilray.

Summary

Aurora Cannabis beats Tilray on 7 of the 13 factors compared between the two stocks.

USANA Health Sciences (NYSE:USNA) and Aurora Cannabis (NYSE:ACB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.

Valuation and Earnings

This table compares USANA Health Sciences and Aurora Cannabis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
USANA Health Sciences$1.06 billion1.57$100.53 million$4.4117.99
Aurora Cannabis$207.89 million8.21$-2,468,190,000.00($2.86)-4.21

USANA Health Sciences has higher revenue and earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for USANA Health Sciences and Aurora Cannabis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
USANA Health Sciences00203.00
Aurora Cannabis412101.82

USANA Health Sciences presently has a consensus price target of $107.00, indicating a potential upside of 34.88%. Aurora Cannabis has a consensus price target of $12.6564, indicating a potential upside of 5.12%. Given USANA Health Sciences' stronger consensus rating and higher probable upside, research analysts clearly believe USANA Health Sciences is more favorable than Aurora Cannabis.

Volatility & Risk

USANA Health Sciences has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 3.44, meaning that its stock price is 244% more volatile than the S&P 500.

Profitability

This table compares USANA Health Sciences and Aurora Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
USANA Health Sciences10.35%32.87%22.28%
Aurora Cannabis-1,238.94%-16.32%-13.12%

Institutional and Insider Ownership

55.5% of USANA Health Sciences shares are owned by institutional investors. Comparatively, 11.9% of Aurora Cannabis shares are owned by institutional investors. 45.4% of USANA Health Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

USANA Health Sciences beats Aurora Cannabis on 12 of the 14 factors compared between the two stocks.

Aurora Cannabis (NYSE:ACB) and HEXO (NYSE:HEXO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Earnings & Valuation

This table compares Aurora Cannabis and HEXO's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$207.89 million8.21$-2,468,190,000.00($2.86)-4.21
HEXO$60.46 million14.57$-406,370,000.00($0.96)-7.51

HEXO has lower revenue, but higher earnings than Aurora Cannabis. HEXO is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Aurora Cannabis and HEXO, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aurora Cannabis412101.82
HEXO69101.69

Aurora Cannabis presently has a consensus target price of $12.6564, indicating a potential upside of 5.12%. HEXO has a consensus target price of $1.15, indicating a potential downside of 84.05%. Given Aurora Cannabis' stronger consensus rating and higher probable upside, analysts plainly believe Aurora Cannabis is more favorable than HEXO.

Risk and Volatility

Aurora Cannabis has a beta of 3.44, suggesting that its share price is 244% more volatile than the S&P 500. Comparatively, HEXO has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.

Profitability

This table compares Aurora Cannabis and HEXO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aurora Cannabis-1,238.94%-16.32%-13.12%
HEXO-517.61%-13.15%-10.35%

Institutional & Insider Ownership

11.9% of Aurora Cannabis shares are held by institutional investors. Comparatively, 35.3% of HEXO shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

HEXO beats Aurora Cannabis on 7 of the 12 factors compared between the two stocks.

Aurora Cannabis (NYSE:ACB) and Sundial Growers (NASDAQ:SNDL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Earnings & Valuation

This table compares Aurora Cannabis and Sundial Growers' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$207.89 million8.21$-2,468,190,000.00($2.86)-4.21
Sundial Growers$75.86 million6.65$-204,570,000.00N/AN/A

Sundial Growers has lower revenue, but higher earnings than Aurora Cannabis.

Analyst Ratings

This is a breakdown of current recommendations for Aurora Cannabis and Sundial Growers, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aurora Cannabis412101.82
Sundial Growers13001.75

Aurora Cannabis presently has a consensus target price of $12.6564, indicating a potential upside of 5.12%. Sundial Growers has a consensus target price of $1.25, indicating a potential upside of 75.17%. Given Sundial Growers' higher probable upside, analysts plainly believe Sundial Growers is more favorable than Aurora Cannabis.

Risk and Volatility

Aurora Cannabis has a beta of 3.44, suggesting that its share price is 244% more volatile than the S&P 500. Comparatively, Sundial Growers has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.

Profitability

This table compares Aurora Cannabis and Sundial Growers' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aurora Cannabis-1,238.94%-16.32%-13.12%
Sundial Growers-362.49%-179.71%-79.40%

Institutional & Insider Ownership

11.9% of Aurora Cannabis shares are held by institutional investors. Comparatively, 10.7% of Sundial Growers shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Aurora Cannabis beats Sundial Growers on 8 of the 12 factors compared between the two stocks.

Aurora Cannabis (NYSE:ACB) and ChromaDex (NASDAQ:CDXC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Earnings & Valuation

This table compares Aurora Cannabis and ChromaDex's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$207.89 million8.21$-2,468,190,000.00($2.86)-4.21
ChromaDex$46.29 million6.23$-32,150,000.00($0.52)-8.98

ChromaDex has lower revenue, but higher earnings than Aurora Cannabis. ChromaDex is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Aurora Cannabis and ChromaDex, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aurora Cannabis412101.82
ChromaDex00303.00

Aurora Cannabis presently has a consensus target price of $12.6564, indicating a potential upside of 5.12%. ChromaDex has a consensus target price of $7.6667, indicating a potential upside of 64.17%. Given ChromaDex's stronger consensus rating and higher probable upside, analysts plainly believe ChromaDex is more favorable than Aurora Cannabis.

Risk and Volatility

Aurora Cannabis has a beta of 3.44, suggesting that its share price is 244% more volatile than the S&P 500. Comparatively, ChromaDex has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500.

Profitability

This table compares Aurora Cannabis and ChromaDex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aurora Cannabis-1,238.94%-16.32%-13.12%
ChromaDex-39.86%-100.14%-50.35%

Institutional & Insider Ownership

11.9% of Aurora Cannabis shares are held by institutional investors. Comparatively, 24.7% of ChromaDex shares are held by institutional investors. 12.9% of ChromaDex shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

ChromaDex beats Aurora Cannabis on 8 of the 14 factors compared between the two stocks.


Aurora Cannabis Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cronos Group logo
CRON
Cronos Group
0.7$10.93+3.0%$3.89 billion$25.64 million45.54High Trading Volume
Decrease in Short Interest
Tilray logo
TLRY
Tilray
0.8$19.70+5.8%$2.63 billion$166.98 million-4.04Analyst Downgrade
Heavy News Reporting
USANA Health Sciences logo
USNA
USANA Health Sciences
1.8$79.33+0.2%$1.67 billion$1.06 billion14.69
HEXO
HEXO
0.7$7.21+1.1%$765.96 million$60.46 million-1.48Increase in Short Interest
Heavy News Reporting
SNDL
Sundial Growers
1.3$0.71+2.8%$504.35 million$75.86 million-0.24
ChromaDex logo
CDXC
ChromaDex
1.3$4.67+0.2%$288.56 million$46.29 million-12.29
MediWound logo
MDWD
MediWound
1.1$5.05+0.4%$131.70 million$31.79 million-12.62Analyst Revision
NAII
Natural Alternatives International
0.4$12.70+0.8%$79.26 million$118.88 million158.77Decrease in Short Interest
HAPP
Happiness Biotech Group
0.6$2.02+3.5%$56.46 million$65.06 million0.00
MTEX
Mannatech
1.1$18.07+0.6%$37.89 million$157.73 million5.56Decrease in Short Interest
Heavy News Reporting
CYAN
Cyanotech
0.8$3.19+1.3%$20.12 million$31.90 million31.90Decrease in Short Interest
Heavy News Reporting
This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.